Latest Ratios: P/E Ratio -0.8x · EV/EBITDA N/A · ROE -105.7%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $8M | $70M | $2M | $850722 | $2M | $11M | $5M | $14M | $11M | $8M | $52M |
| Enterprise Value | $3M | $65M | $1M | $-4138278 | $-2482980 | $2M | $3M | $13M | $7M | $7M | $41M |
| P/E Ratio → | -0.76 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 3.53 | 31.57 | 1.24 | 0.71 | 1.90 | 19.02 | 20.10 | 100.29 | 38.22 | 151.59 | 164.91 |
| P/B Ratio | 5.10 | 7.33 | 0.92 | 0.13 | 0.37 | 1.09 | 1.34 | 5.59 | 1.80 | 1.05 | 4.83 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 29.36 | 0.68 | -3.47 | -2.44 | 3.80 | 11.57 | 93.42 | 23.28 | 126.19 | 128.41 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 62.5% | 62.5% | 54.1% | 45.2% | 45.5% | 38.2% | -8.9% | 29.4% | 18.9% | 13.5% | 38.4% |
| Operating Margin | -292.9% | -292.9% | -336.5% | -648.1% | -949.4% | -1551.0% | -3074.8% | -7193.7% | -4000.0% | -23684.6% | -3306.9% |
| Net Profit Margin | -287.4% | -287.4% | -333.0% | -646.3% | -951.4% | -1435.4% | -3076.4% | -7005.6% | -4009.4% | -23626.9% | -3394.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -105.7% | -105.7% | -139.6% | -132.6% | -126.6% | -118.8% | -246.1% | -225.6% | -172.1% | -133.9% | -309.3% |
| ROA | -79.2% | -79.2% | -117.0% | -109.6% | -106.1% | -94.4% | -144.3% | -157.4% | -139.5% | -110.7% | -156.3% |
| ROIC | -159.0% | -159.0% | -331.5% | -521.3% | -682.2% | -454.7% | -364.1% | -446.1% | -220.7% | -340.8% | — |
| ROCE | -88.1% | -88.1% | -135.5% | -129.2% | -120.8% | -113.2% | -183.9% | -206.0% | -161.1% | -128.1% | -214.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.28 | 0.28 | 0.10 | 0.06 | 0.07 | 0.06 | 0.37 | 0.37 | 0.08 | 0.10 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.51 | -0.42 | -0.79 | -0.84 | -0.87 | -0.57 | -0.38 | -0.70 | -0.18 | -1.07 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -289.14 | -289.14 | -280.09 | -1926.50 | -4846.50 | -750.64 | -282.46 | -237.52 | -159.92 | -141.86 | -123.08 |
Net cash position: cash ($8M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.61 | 12.61 | 5.01 | 8.49 | 4.62 | 11.30 | 6.07 | 2.24 | 5.74 | 6.73 | 6.81 |
| Quick Ratio | 11.36 | 11.36 | 3.60 | 7.48 | 3.98 | 10.24 | 4.88 | 1.49 | 4.65 | 6.27 | 6.77 |
| Cash Ratio | 10.74 | 10.74 | 2.33 | 6.86 | 3.61 | 9.89 | 4.59 | 1.22 | 4.23 | 6.09 | 6.58 |
| Asset Turnover | — | 0.17 | 0.57 | 0.16 | 0.15 | 0.05 | 0.04 | 0.03 | 0.04 | 0.01 | 0.02 |
| Inventory Turnover | 0.84 | 0.84 | 1.07 | 0.82 | 0.65 | 0.36 | 0.30 | 0.09 | 0.19 | 0.08 | 3.44 |
| Days Sales Outstanding | — | 33.03 | 65.85 | 29.07 | 40.48 | 48.79 | 35.37 | 380.31 | 170.82 | 112.31 | 11.48 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | 8.4% | — | — | — | 0.3% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 8.4% | 0.0% | 0.0% | 0.0% | 0.3% |
| Shares Outstanding | — | $33M | $697974 | $66986 | $5211 | $4663 | $1252 | $543 | $404 | $228 | $134 |
Persistent operating cash burn
As reported in recent financial filings, SenesTech trades at a price-to-sales ratio of 3.74, a valuation that appears disconnected from its negative earnings profile and suggests investors are pricing in significant future adoption rather than current fundamental performance within the specialty chemical sector.
The absence of a meaningful P/E or EV/EBITDA multiple underscores the market's reliance on top-line growth expectations to justify the current share price. Investors should monitor whether this premium valuation can be sustained if revenue growth fails to accelerate beyond the current 19.60% year-over-year rate.
Based on historical data, SenesTech's ROIC has consistently languished in negative territory, reaching -38.8% in 2026Q1, which indicates that the company is currently destroying shareholder value rather than compounding it through its specialized rodent control product deployments.
The persistent negative return on capital suggests that the costs associated with regulatory compliance and market education are not being offset by the margins generated from ContraPest sales. This trend warrants further investigation into whether the company can ever achieve a positive spread between its cost of capital and its return on invested assets.
According to quarterly financial statements, the company's cash conversion cycle remains highly elevated, peaking at 457 days in 2026Q1, which highlights significant friction in converting inventory into cash compared to more mature chemical industry peers.
The extremely high days inventory outstanding suggests that the company may be struggling with product sell-through or is maintaining excessive stock levels in anticipation of demand that has yet to materialize. This inefficiency ties up critical liquidity and exacerbates the company's reliance on external financing.
As reported in recent balance sheet data, SenesTech maintains a low debt-to-equity ratio of 0.34, yet this appears to be a function of persistent equity dilution rather than a robust, self-funding capital structure capable of supporting long-term operations.
While the low leverage ratio might appear favorable, it obscures the reality that the company is effectively financing its operating losses through the continuous issuance of shares. Investors should monitor the potential for further dilution as the company attempts to bridge the gap between its current cash burn and eventual profitability.
Based on the provided figures, the 62.49% gross margin is frequently misapplied as a proxy for operational health, obscuring the fact that the company's massive SG&A burden renders the business model fundamentally unprofitable at current revenue scales.
Focusing on gross margin ignores the reality that the company's primary competitive advantage—its regulatory exclusivity—requires an expensive, ongoing educational sales effort that is not captured in cost of goods sold. Analysts should prioritize operating margin and cash burn metrics over gross margin to better assess the company's path to self-sustainability.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SNES stock.
SenesTech, Inc.'s current P/E ratio is -0.8x. This places it at the 50th percentile of its historical range.
SenesTech, Inc.'s return on equity (ROE) is -105.7%. The historical average is -171.0%.
Based on historical data, SenesTech, Inc. is trading at a P/E of -0.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
SenesTech, Inc. has 62.5% gross margin and -292.9% operating margin.